



AMERICAN SOCIETY OF TROPICAL MEDICINE & HYGIENE  
ADVANCING GLOBAL HEALTH SINCE 1903

VOLUME 103    NOVEMBER 2020    NUMBER 5 SUPPLEMENT

# 2020 ANNUAL MEETING

NOVEMBER 15–19 | *VIRTUAL MEETING*



[astmh.org](http://astmh.org) | [ajtmh.org](http://ajtmh.org) | [#TropMed20](https://twitter.com/TropMed20) [#lamTropMed](https://twitter.com/lamTropMed) [f](#) [t](#) [v](#) [in](#)



Supplement to  
The American Journal of Tropical Medicine and Hygiene



# Sponsored Symposia

## Re-starting Malaria R&D in the Face of COVID-19

***Sponsored by the RBM Partnership to End Malaria, the European Developing Countries Clinical Trials Partnership and Medicines for Malaria Ventures***

*Meeting Room 2*

**Tuesday, November 17, 6:45 a.m. – 8:30 a.m.**

COVID-19 has put a halt to much of the health research happening worldwide. It is vital that malaria R&D clinical trials are re-started as soon as possible to ensure that we do not lose valuable time bringing much-needed innovations to market. This session will share perspective from research programmes and funders on how COVID-19 has affected their operations and their planning for re-starting R&D in a safe and effective manner. Holding this symposium will allow stakeholders to share their learnings about re-starting R&D in the face of COVID-19.

### **SETTING THE STAGE ON MALARIA IN AFRICA AND DISCUSSING THE IMPORTANCE OF NEW TOOLS TO FIGHT MALARIA AND RE-STARTING R&D AND CLINICAL TRIALS AS SOON AS POSSIBLE**

Co-Chair: Abdourahmane Diallo

*CEO, The RBM Partnership to End Malaria, Geneva, Switzerland*

### **ADDRESSING THE SITUATION ON THE GROUND IN CONDUCTING CLINICAL TRIALS**

Co-Chair: Bernhards Ogutu

*Chief Research Officer, Kenya Medical Research Institute (KEMRI) and Senior Clinical Trialist, Malaria Clinical Trials Alliance of the INDEPTH-Network, Nairobi, Kenya*

### **DISCUSSION OF WHITE PAPER ON INNOVATION AND OVERALL VIEWS ON INNOVATION AND ACCESS ON THE CONTINENT**

Catherine Kyobutuni

*Executive Director, African Population and Health Research Centre, Nairobi, Kenya*

### **HOW COVID-19 HAS AFFECTED NOVARTIS R&D TIMELINES AND INITIAL LEARNINGS FROM RE-STARTING TRIALS**

Caroline Boulton

*Global Programme Head, Malaria, Novartis, Basel, Switzerland*

### **HOW COVID-19 HAS AFFECTED THEIR R&D PARTNERSHIPS, HOW THEY HAVE BEEN DOING SCENARIO PLANNING AND HOW FUNDING STREAMS HAVE BEEN AFFECTED**

David Reddy

*CEO, Medicines for Malaria Venture, Geneva, Switzerland*

### **HOW EDCTP IS HANDLING THE IMPACT OF COVID-19 ON R&D AS A FUNDER**

Michael Makanga

*CEO, European & Developing Countries Clinical Trials Partnership, The Hague, Netherlands*

### **INFORMING R&D PRIORITIES THROUGH AFRICAN-WIDE DIGITAL PLATFORM FOR INFECTIOUS DISEASES**

Lacina Koné

*Director General, Smart Africa, Kigali, Rwanda*